Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) and daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma Meeting Abstract

  

Authors:	Tan, C.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; Shekarkhand, T.; Rueda, C.; Lahoud, O. B.; Shah, G. L.; Scordo, M.; Chung, D.; Landau, H.; Giralt, S. A.; Lesokhin, A.; Usmani, S. Z.
Abstract Title:	Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) and daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
Meeting Title:	65th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	142
Issue:	Suppl. 1
Meeting Dates:	2023 Dec 9-12
Meeting Location:	San Deigo, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2023-11-02
Start Page:	4744
Language:	English
ACCESSION:	WOS:001159740308233
DOI:	10.1182/blood-2023-181868
PROVIDER:	wos
Notes:	Meeting Abstract -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/215343